A2M has been shown to have strong tumour-suppressor properties in astrocytoma cells, possibly by interfering with ß-catenin signalling57, and it was recently used to mediate tumour antigen presentation in cancer immunotherapy58. Here, A2M is linked to astrocytoma (excluding glioblastoma).